UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 13D/13G Filings for Prelude Therapeutics Incorporated (PRLD)

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 13D and 13G filings for Prelude Therapeutics Incorporated:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime
Transaction
Date
TypeCompany
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev ReportView
2024-02-13
1:34 pm
Sale
2023-12-3113GPrelude Therapeutics Incorporated
PRLD
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC0
0.000%
-2,507,992decrease
(Position Closed)
Filing
2023-02-13
10:52 am
Purchase
2022-12-3013GPrelude Therapeutics Incorporated
PRLD
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC2,507,992
5.240%
2,507,992increase
(New Position)
Filing